ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstracts tagged "5-HT"

  • Abstract Number: 1769 • 2019 ACR/ARP Annual Meeting

    Myosin Regulation of TNF Receptor 2 Signaling May Contribute to Anti-TNF Therapy Response

    Unnikrishnan M Chandrasekharan1, Jennifer Harvey 2, Mackenzie Dunlap 2, Marcia Leon Rabanal 2, Vandana Rai 2 and M. Elaine Husni 3, 1Cleveland clinic foundation, Cleveland, OH, 2Cleveland clinic, Cleveland, 3Department of Rheumatologic and Immunologic Diseases, Cleveland Clinic, Cleveland, OH

    Background/Purpose: Background/Purpose:Anti-TNF agents have revolutionized the clinical outcomes of patients with  rheumatoid and psoriatic diseases. However, up to 40% of patients do not respond or…
  • Abstract Number: 1857 • 2016 ACR/ARHP Annual Meeting

    A Novel Highly Selective 5-Hydroxytryptamine 2B (5-HT2B) Receptor Antagonist Ameliorating Fibrosis in Preclinical Models of Systemic Sclerosis

    Christina Wenglén1, Lars Pettersson2, Helena Arozenius2 and Gunilla Ekström1, 1R&D, AnaMar AB, Lund, Sweden, 2AnaMar AB, Lund, Sweden

    Background/Purpose:   Methods:   Results:   Conclusion: The results demonstrate that the 5-HT2B receptor antagonist AM1125 prevents pro-fibrotic events in human dermal fibroblasts and attenuates…
  • Abstract Number: 960 • 2012 ACR/ARHP Annual Meeting

    Cyclobenzaprine (CBP) and Its Major Metabolite Norcyclobenzaprine (nCBP) Are Potent Antagonists of Human Serotonin Receptor 2a (5HT2a), Histamine Receptor H-1 and á-Adrenergic Receptors: Mechanistic and Safety Implications for Treating Fibromyalgia Syndrome by Improving Sleep Quality

    Bruce Daugherty, Leland Gershell and Seth Lederman, Research and Development, Tonix Pharmaceuticals, Inc., New York, NY

    Background/Purpose: Bedtime cyclobenzaprine (CBP) improves fibromyalgia symptoms (pain, fatigue, tenderness, and mood) and improves sleep quality (decreases Cyclic Alternating Pattern Type A2 + A3) (1).…
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

© COPYRIGHT 2023 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences